The University of Texas System

Ashvin R Jaiswal

Bianka Prinz

Dongxing Zha

Michael A Curran

Carlo Toniatti

Kui Shin Voo

Nadthakarn Boland

Eric Krauland

Nga Rewa Houston

Kui Voo

The present disclosure is directed to antibodies binding to PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L2.

Human PD-L2 antibodies and methods of use therefor

The present disclosure is directed to antibodies binding to PD-L1 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1.

Human PD-L1 antibodies and methods of use therefor

The present disclosure is directed to dual specificity antibodies which may bind to PD-L1 or PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1 or PD-L2.

Dual specificity antibodies to PD-L1 and PD-L2 and methods of use therefor

The present disclosure is directed to bispecific antibodies which bind to both PD-L1 and PD-L2, and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1, PD-L2, or both.

Growing community of inventors

Houston, TX, United States of America

Ashvin R Jaiswal